BOLD Longevity Growth takes a science-first approach to longevity investing, backing companies whose platform technologies target biological aging as the root of disease rather than a single condition. It concentrates on platform technologies that carry multiple assets and joins growth-stage rounds alongside larger venture, pharmaceutical, and technology co-investors.

Its investment focus spans gene therapies and editing, cell therapies and regenerative medicine, AI drug discovery and early diagnostics, and AI-powered medtech and biosensing. The firm is one of few funds investing in late-stage longevity technology and targets seasoned biotechnology executives advancing longevity and biotechnologies.